Abstract Body

Dolutegravir (DTG) is a potent and well tolerated integrase strand-transfer inhibitor (INSTI) with a high barrier to resistance, which makes it a suitable candidate for antiretroviral maintenance monotherapy and simplified regimens. Here, we report the emergence of a S230R substitution in two patients who experienced virological failure after switching to DTG monotherapy from triple therapy and have characterized the effects of S230R on integrase (IN) enzyme activity, viral infectivity and drug resistance.

IN-resistance associated mutations were evaluated by sequencing both prior to and at the time of virologic failure. The pET15b-IN overexpression and pNL4.3 proviral vectors containing S230R were generated by site-directed mutagenesis. Biochemical strand-transfer and tissue culture assays were performed to characterize enzyme activity, viral infectivity and to measure resistance to DTG and other INSTIs.

The first case of S230R was found in the context of the DOMONO study (NCT02401828) in a patient who experienced virologic failure at week 30 (HIV-1 RNA was 1570 copies/mL). The patient had a CD4 nadir of 330 cells/mm3 and had been virologically suppressed on EFV/TDF/FTC for 25 months before switching to DTG 50 mg once daily. A second case involved a patient who had been virologically suppressed on DTG/ABC/3TC for 8 months before switching to DTG monotherapy. Viral load (VL) remained <20 copies/mL but increased to 700 copies/mL with the presence of S230R in IN at week 29. The results of cell-free assays showed that, compared to the WT-IN (Km = 8.8 ± 0.95), the S230R-IN had a modest 2.22-fold increase in Km (19.9 ± 2.3). In the presence of DTG, yielding a 2.6- fold decrease in DTG susceptibility. The infectivity of S230R virus was also impaired by about 1.26-fold compared to WT. The relevance of the S230R substitution was confirmed in a recent study, where DTG monotherapy failed to durably suppress HIV viremia in humanized mice.

In conclusion, virological failure involving DTG monotherapy can occur due to replication of a virus containing a novel S230R substitution that confers modest-level resistance to DTG and other INSTIs.